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Abstract
Drug Induced Liver Injury (DILI) is one of the main causes of drug attrition. The ability to predict
the liver effects of drug candidates from their chemical structure is critical to help guiding
experimental drug discovery projects towards safer medicines. In this study, we have compiled a
dataset of 951 compounds reported to produce a wide range of effects in the liver in different species,
comprising humans, rodents, and non-rodents. The liver effects for this dataset were obtained as
assertional meta-data, generated from MEDLINE abstracts using a unique combination of lexical
and linguistic methods and ontological rules. We have analyzed this dataset using conventional
cheminformatics approaches and addressed several questions pertaining to cross-species
concordance of liver effects, chemical determinants of liver effects in humans, and the prediction of
whether a given compound is likely to cause a liver effect in humans. We found that the concordance
of liver effects was relatively low (ca. 39–44%) between different species raising the possibility that
species specificity could depend on specific features of chemical structure. Compounds were
clustered by their chemical similarity, and similar compounds were examined for the expected
similarity of their species-dependent liver effect profiles. In most cases, similar profiles were
observed for members of the same cluster, but some compounds appeared as outliers. The outliers
were the subject of focused assertion re-generation from MEDLINE, as well as other data sources.
In some cases, additional biological assertions were identified which were in line with expectations
based on compounds' chemical similarity. The assertions were further converted to binary
annotations of underlying chemicals (i.e., liver effect vs. no liver effect), and binary QSAR models
were generated to predict whether a compound would be expected to produce liver effects in humans.
Despite the apparent heterogeneity of data, models have shown good predictive power assessed by
external five-fold cross validation procedures. The external predictive power of binary QSAR models
was further confirmed by their application to compounds that were retrieved or studied after the
model was developed. To the best of our knowledge, this is the first study for chemical toxicity
prediction that applied QSAR modeling and other cheminformatics techniques to observational data
generated by the means of automated text mining with limited manual curation, opening up new
opportunities for generating and modeling chemical toxicology data.
1. Introduction
Drug Induced Liver Injury (DILI) is widely regarded as a leading cause of drug attrition both
during clinical development and post-approval (1) and therefore it constitutes a major safety
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concern for drug development (2–6). Elimination of drug candidates likely to cause
hepatotoxicity at early stages of drug discovery could significantly decrease the rate of attrition
and cut the cost of drug development. There is a great deal of interest both in the US (cf. the
ToxCast program, http://www.epa.gov/ncct/toxcast/) and Europe (cf. the REACH program,
http://ec.europa.eu/environment/chemicals/reach.htm) in developing fast and accurate
experimental and computational approaches to predicting toxic effects of chemicals including
hepatotoxicity. Experimental approaches have focused on the development of various in
vitro assays (4;7–9) that can be used to assess the in vivo effects. Farkas and Tannenbaum
(8) as well as Sutter (7) published very detailed reviews about different in vitro hepatotoxicity
assessing techniques. O'Brien et al. (4) demonstrated that most conventional assays that
measure cytotoxicity have a poor concordance with human toxicity. However, they still point
out the great predictive accuracy of certain assays that evaluate oxidative stress, mitochondrial
reductive activity and cell proliferation. In addition, O'Brien et al. suggested a novel promising
strategy (involving the High Content Screening (HCS) technique) to monitor cytotoxicity
biomarkers in human hepatocytes exposed to drugs and demonstrated good concordance of
such in vitro results with drug-induced human hepatotoxicity. In another recent study, Xu et
al. (10) reported testing of ca. 300 drugs and chemicals on human hepatocytes for their induced
effects (mitochondrial damage, oxidative stress and intracellular glutathione, all measured by
HCS imaging assay technology). Xu et al. obtained a true positive rate of 50–60% with very
few false-positives. Recent studies, e.g., Blomme et al. (11) or Elferink et al. (12), showed
promising results concerning the prediction of in vivo hepatotoxicity from microarray analysis
of gene expression profiles (extracted from rat livers treated with a given drug).
Computational predictors of hepatotoxicity have been developed as well. For instance, a
classification recursive partitioning model was developed based on 1D and 2D molecular
descriptors that was trained using an ensemble of 143 compounds inducing liver injuries and
233 non-toxic molecules (13). A COMFA based approach was utilized (14) for the
classification of 654 drugs, which have been experimentally tested using different in vitro
assays to characterize their biological effects on liver. The MCASE program (15) was used to
analyze liver toxicity and identify molecular fragments likely to be responsible for liver toxicity
using a dataset of 400 drugs. Cruz-Monteagudo et al. (16) employed a Linear Discriminant
Analysis (LDA) to build models capable of classifying correctly 74 drugs, of which 33 drugs
were known as idiosyncratic hepatotoxicants and 41 did not cause this effect. Their models
afforded impressive external prediction accuracies ranging from 78 to 86%. Egan et al. (3)
have compiled a dataset of 244 molecules from published data and derived a series of 74
computational alerts based on specific molecular functional groups. However, there still
remains a challenge in developing accurate predictors of DILI based on compound structure
for several reasons: (i) the relationships between in vitro assays and in vivo hepatotoxicity are
not yet well understood, (ii) the available Quantitative Structure-Activity Relationships
(QSAR) models, obtained using small datasets of congeneric molecules, are not applicable to
enable prediction of DILI for chemically diverse external sets.
The Safety Intelligence Program (SIP) is an industry-sponsored initiative that aims to build the
world's most comprehensive intelligence resource to support drug safety assessments
(http://www.biowisdom.com/content/safety-intelligence-program). SIP exploits
BioWisdom's Sofia™ platform (http://www.biowisdom.com) to generate assertional meta-
data, which comprises thousands of highly accurate and comprehensive observational
statements. These statements are represented in triple constructs:
concept_relationship_concept, e.g. Cafestol_suppresses_Bile acid biosynthesis,
Azathioprine_induces_Cholestasis etc. Each assertion is derived from and evidenced by a
variety of electronic data sources. Behind each assertion is a rich vocabulary (developed by
BioWisdom) that renders that assertion semantically consistent with the other assertions around
the same concept. For example, the liver pathology term, cholestasis can be described across
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the literature as bile stasis, biliary stasis, cholestasia, cholestatic injury, biliary stases.
Assertional meta-data generated in this manner facilitates the semantically consistent
integration of disparate observations across historic literature. The Program has set a high
standard of accuracy for the generation of the assertional meta-data (>97% chance that the
statement accurately represents that made by the author). This enables the meta-data to be used
for sophisticated assertional meta-analyses, such as that described in this study. Given the
widespread issues associated with DILI, this study uses a subset of SIP assertions which focus
on chemicals known to produce effects in the liver.
Recently, SIP initiated an ambitious study to use assertional meta-data to determine the level
of concordance across various species for drug-induced liver effects
(http://www.biowisdom.com/files/SIP_Board_Species_Concordance.pdf). Using assertions
generated from MEDLINE abstracts and the European Medicines Agency European Public
Assessment Reports (EMEA EPARs;
http://www.emea.europa.eu/htms/human/epar/eparintro.htm), the study showed that 38–51%
of drug-induced liver effects in humans are not detected in preclinical species. These findings
are in general agreement with the previous work of others (17).
In this study, we exploit the assertional meta-data derived from this initial concordance study
to investigate the relationship between chemical structure and species-selectivity of liver
effects. Specifically, a set of 1061 compounds was derived from the assertional meta-data
referenced by MEDLINE abstracts. Each compound in this dataset was reported in the literature
to induce or modify one or more liver effects. The liver effects included in the study are both
pathological and physiological events, owing to the fact that interruption of normal function
and the development of pathology are tightly associated. For example, cholestasis can arise
from the inhibition of bile transport; the development of cancer may result from the
dysregulation of apoptosis or cell cycle; and compounds that interrupt collagen metabolism
are associated with liver fibrosis. Importantly, the assertional meta-data has been collected
across different species, i.e., human, rodent (mostly rat and mouse) and non-rodent animals
(mostly dog), and this allows consideration of species-dependent effects in this analysis. To
our knowledge, this is the largest available molecular dataset containing information on
chemically-induced liver effects and, thus, it allows one to ask important questions about the
relationship between chemical structure and species-selectivity of liver effects.
The study was conducted in an ordered and iterative workflow (see inside hash lines in Figure
1) starting with chemical curation of the molecular dataset, and re-assessment of the liver effect
concordance across species. Next, we have applied standard cheminformatics procedures such
as clustering by chemical similarity to the set of 951 compounds (left after the thorough
chemical curation). This allowed us to identify multiple clusters of congeneric compounds and
explore the concordance between chemical similarity and liver effect profiles across species.
Finally, we have transformed the assertion data into binary liver effect profiles across species
and applied binary QSAR modelling approaches to the resulting dataset. We show that the use
of cheminformatics approaches in the analysis of toxicity assertions mined from the literature
can identify apparent gaps in this dataset, leading to its refinement, as well as afford statistically
robust and externally predictive models of chemical effects on the liver. To the best of our
knowledge studies reported in this paper present the first instance of successful application of
cheminformatics based analytical approaches to non-traditional chemical toxicity data (i.e.,
assertions) generated by ontology-based semi-automated text mining.
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2.1.1. Generation of relevant assertions in MEDLINE abstracts using the Sofia
platform—A collection of MEDLINE abstracts relevant to drug-induced liver effects was
defined by querying all MEDLINE titles and abstracts with a list of terms relating to
hepatobiliary anatomy and pathology, e.g. liver, hepatic, cholestasis and biliary. Assertion
generation was carried out on the resulting corpus, comprising approximately 650,000
MEDLINE records, using BioWisdom's Sofia™ platform. A combination of lexical and
linguistic tools was used to extract relationships that exist between any therapeutic compound
(i.e. that has been or is used in the clinic) and a range of liver pathologies, e.g. hepatitis and
focal necrosis, and hepatic physiological observations such as gluconeogenesis and cell growth.
The use of several extraction methods, which differ in their level of recall and accuracy, ensures
that the assertion generation process provides the most rapid, systematic and unbiased coverage
possible. The extraction procedure was directed at the injurious effects of compounds by
focusing on relationships that imply causation or regulation, such as
Clozapine_induces_Hepatic Necrosis and Propofol_influences_Hepatic Lipid Metabolism,
rather than the associations that imply therapeutic benefit such as treats. This yielded a set of
“proto-assertions”, composed of concept_relationship_concept triplets, together with species,
tissue or cell type/cell line information. All of these elements were manually validated to
achieve an accuracy level of greater than 97%, confirmed by random sampling and quality
control testing. For this study, we used 14,609 assertions, which contained 1061 therapeutic
compounds and 2099 biomedical observations (comprising 424 pathological and 1675
physiological effects).
To allow the correspondence of compound-induced liver effects to be assessed in human,
rodents and non-rodents, the non-human species were classified as either rodent (rat, mouse,
hamster, guinea pig and rodent) or non-rodent (dog, cat, pig, monkey, goat, rabbit and sheep).
Thereafter, compounds inducing liver effects across the various species were assigned to the
appropriate group; for instance, the assertion “Acetaminophen induces Acute Liver Failure
(rat)” resulted in the addition of Acetaminophen to the rodent species group. A profile of
compounds for each group was thus created, and the concordance of the three groups was
visualised in the form of a pivot chart and Venn diagram (Table 1, Figure 2).
2.2.2. Chemical data curation—Data curation is a critical procedure in the analysis of any
chemical dataset, as is particularly evident from the recent study on the detrimental effect of
the incorrect representation of chemical structure on the quality of QSAR models (18). We
have employed both automatic and manual procedures to the initial dataset of 1061 molecular
structures defined by the assertional meta-data as follows:
- First, all inorganic compounds have been removed since our data analysis strategy includes
the calculation of molecular descriptors for organic compounds only. This is an obvious
limitation of our analysis since inorganic molecules are definitely known to induce diverse
liver injuries; however the total fraction of inorganics in our dataset was relatively small. Thus,
the following compounds have been removed from our dataset: activated charcoal, cobalt
dichloride, ferrous sulphate, zinc chloride, sulphur, cis-diaminedichloroplatinum, manganese
chloride etc. Moreover, additional compounds were removed because (i) their corresponding
SMILE strings were impossible to retrieve despite many efforts, or (ii) they corresponded to
mixtures of compounds (for example, Gramicidin, which is a product containing six different
antibiotic molecules).
- 2D molecular structures (chemical connectivity maps) were generated from SMILE strings
using the JChem 5.0 program of ChemAxon (http://www.chemaxon.com). We also used the
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Standardizer module of JChem to remove all counter-ions, clean records including multiple
compounds, clean the 2D molecular geometries and normalize bonds (aromatic, nitro groups
etc.) of the 989 remaining compounds.
- Duplicate molecular structures were automatically detected and deleted using the ISIDA/
Duplicates (http://infochim.u-strasbg.fr) program, followed by careful manual inspection of
the entire dataset. Finally, 951 compounds remained out of the initial 1061 molecules. Once
again, it should be pointed out that such laborious but necessary steps of data curation are one
of the critical stages of this study, making the following results more pertinent and valid (18).
2.2. QSAR modeling
2.2.1. Substructural Molecular Fragments (SMFs)—The ISIDA/Fragmentor program
(19) (freely available from http://infochim.u-strasbg.fr) was employed to calculate 2D SMFs
for all compounds. Briefly, each molecular structure is split into small chemical patterns (see
Figure 3). Two different types of fragments were considered: “sequences” (I) and “augmented
atoms” (II). Three sub-types AB, A and B are defined for each class. For the fragments I, they
represent sequences of atoms and bonds (AB), of atoms only (A), or of bonds only (B). Only
shortest paths from one atom to another are used. For each type of sequences, the minimal
(nmin) and maximal (nmax) number of constituted atoms are defined (for this study, nmin = 2
and nmax = 7). An “augmented atom” represents a selected atom with its environment including
either both neighbouring atoms and bonds (AB), or atoms only (A), or bonds only (B). Atomic
hybridization (Hy) has been taken into account for augmented atoms. Unlike structural keys,
there is no predefined library of fragments. In this study involving 951 compounds, fragment
descriptors were rapidly calculated by the ISIDA/Fragmentor program: 1466 fragments
remained after the deletion of invariants, low variance and highly correlated ones. Moreover,
fragment descriptors are directly linkable to the chemical structure of compounds. As a
consequence, QSAR models involving fragments are highly suitable for virtual screening of
large sets of compounds as well as for defining structural alerts. Cluster analysis in
cheminformatics as well as QSAR modeling is also commonly performed using molecular
fingerprints like structural keys or such types of fragment descriptors (20;21). Small fragments
do not represent the complexity of chemical compounds by themselves. However, in
combination, multiple descriptors do reflect the structure complexity. In this work, the use of
an ensemble of fragment descriptors afforded better segregation between compound classes
using clustering and machine learning techniques.
2.2.2. Hierarchical Cluster Analysis—The clustering of a chemical dataset consists of
merging compounds into independent clusters that include chemically similar molecules (see
recent publications (22;23) for the review of the most popular clustering approaches used in
computational chemistry). In this study, we have employed the Sequential Agglomerative
Hierarchical Non-overlapping (SAHN) method implemented in the ISIDA/Cluster program
(http://infochim.u-strasbg.fr) (24). Briefly, each compound represents one cluster at the start.
Then, the m compounds are merged iteratively into clusters using their pairwise Euclidean
distances stored in a squared m * m symmetric distance matrix. At each iteration, the two closest
objects (molecules or clusters) are merged to form a new cluster and then, the distance matrix
is updated with the distances between the newly formed cluster and the others, according to
the user-specified type of linkage (single, average, complete or Ward type). The process is
repeated until one cluster remains. The parent-child relationships between clusters result in a
hierarchical data representation, or dendrogram. SAHN algorithms are only appropriate to treat
relatively small datasets (several thousands) in high dimensional space due to their O(N3) time
and O(N2) space requirements. ISIDA/Cluster allows visualization of molecular structures in
each cluster, directly on the dendrogram, and has multiple options to facilitate the analysis of
results and export contents of selected clusters. In particular, we used ISIDA/Cluster to obtain
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the heat map of the proximity matrix, as well as the dynamic dendrogram of compound clusters
(see Figure 4).
2.2.3. Support Vector Machines (SVM) approach—The description of the original
SVM algorithm could be found in many publications (25). Briefly, molecular descriptors are
first mapped onto a high dimensional feature space using various kernel functions, and then a
linear model is constructed in this feature space to segregate compounds with different
activities. Models built with this machine learning technique allow the prediction of a target
property using a set of descriptors solely calculated from the structure of a given compound.
Best practices to derive and select the best models with high predictive abilities from a modeling
set have been detailed elsewhere (26). For SVM classification, we used WinSVM program
developed in our group at UNC (available upon request) implementing the open-source libsvm
package (http://www.csie.ntu.edu.tw/~cjlin/libsvm/). The WinSVM program provides users
with a convenient graphical interface to prepare input data, to split compounds into training,
test and validation sets, to set up parameters for SVM grid calculations (iterative and
simultaneous grid optimization of SVM parameters), to launch and follow calculation progress
in a powerful graphical interface, to select models with the best prediction performances on
both training and internal test sets, and then apply them for the external test set as an ensemble
consensus model with its defined applicability domain. The program also allows one to
visualize molecular structures and various plots, making the use of SVM easier and more
appropriate for QSAR modeling, in order to obtain robust and predictive models and apply
them to virtual libraries as well.
3. Results
3.1. Assessment of the concordance of liver effects across species
As described in section 2.2, 951 compounds remained after the chemical curation of the dataset
obtained from assertions generated from MEDLINE abstracts by Sofia. We have reorganised
these data in the form of a set of liver effect profiles for each compound (see Table 1): if a
compound was found to have a reported liver effect in a species (human - A, rodent - B or non-
rodent - C), its corresponding cell in Table 1 was given the value of “1”. To enable the
concordance analysis, we have made an assumption that every compound was tested in all
three species. Thus, if no effect was reported for a compound in the assertional meta-data for
a given species, we have assumed that the compound does not exert liver effects in that species.
Consequently, the cell is given the value “0”. Following this, molecules have been classified
as having a liver effect for one species only (A only or B only or C only), two species (AB,
AC or BC) or all three species (ABC) (Table 1, right hand side). Note that by design, the dataset
did not include any compound that reported no liver effect in any species. To visualize this
dataset and illustrate the overlaps between species categories, a Venn diagram was generated
(Figure 2).
All 951 compounds are represented on the Venn diagram: 650 molecules among them have
been identified as causing liver effects in humans; 685 showed liver effects in rodents, and 166
in non-rodents. 110 molecules were reported to have liver effects in all three species.
Furthermore, a total of 402 (292 + 110) compounds reported liver effects in both humans and
rodents, whereas a total of 122 compounds reported liver effects in both humans and non-
rodents. We provide additional comments concerning the validity and the limits of such
splitting in the discussion part.
These data were used to address the important question of concordance between drug-induced
liver effects reported in different species. We have defined the concordance between two
species, e.g., humans (A) and rodents (B), as CONC(A,B), according to the following formula:
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Where the sum of the numbers of toxicants and non-toxicants for both species A and B, is
divided by the total of tested chemicals. We have applied this formula to calculate the
concordance between species with the following results:
(i) Humans-A and rodents-B: CONC(A,B) = (292 + 110 + 18)/951 = 44.2 %,
(ii) Humans-A and non-rodents-C: CONC(A,C) = (110 + 12 + 257)/951 = 39.9 %,
(iii) Rodents-B and non-rodents-C: CONC(B,C) = (110 + 26 + 236)/951 = 39.1 %.
The difference between concordances (less than 5 %) was found to be very small. Certainly,
we have to stress that these results are valid if and only if our underlying assumption is correct,
i.e., that each compound has been effectively tested in all species groups (A, B and C), and in
each case, where liver effects are found, it is reported in the assertional meta-data. Nevertheless,
with this assumption in mind, the results suggest that animal testing in many cases may be
inconclusive with respect to the expected liver effects in humans. Central to these species-
specific effects may be differences in the specificity and affinity of chemicals interacting with
their targets in different species. There are many examples of species differences in ligand
binding to key receptors, enzymes and transporters between species, all of which could
influence physiological and ultimately pathological outcomes. One should also consider the
differences in doses of compounds administered in rodents vs. humans.
It is also useful to examine conclusions about the concordance between species-specific liver
effects using prior probabilities, which are conceptually more simple and perhaps more
intuitively obvious than the Conc(A,B) function described above. The prior probabilities could
be formally established by calculating the fraction of compounds reporting liver effects in one
species that are also known to produce liver effects in another species. However, as we
demonstrate below, the use of prior probabilities with these unbalanced datasets could lead to
opposite (and therefore, confusing) conclusions. Indeed,
(i) Among compounds that report liver effects in humans (650), 62 % (312/650) also
report liver effects in rodents, while only 19 % (112/650) report liver effects in non-
rodents.
(ii) On the other hand, if we consider compounds with reported liver effects in non-rodents
(166), 73 % (112/166) of them also have reported liver effects in humans, while only
59 % (312/685) also have reported liver effects for humans.
These two series of statements, based on prior probability calculations, lead to opposite
conclusions about the concordance between species. Specifically, prior probabilities tend to
show a significant concordance for liver effects between non-rodents and humans (73%); on
the contrary, that concordance value (for non-rodents and humans) calculated using Eq.1 is
equal to 40% only. However, recent experimental studies (4;27;28) support the concordance
results (40–44%) calculated using Eq. 1. Indeed, it was recently noted (4) that “hepatotoxicity
has the poorest correlation with regulatory animal toxicity test. In only approximately half of
the new pharmaceuticals that produced hepatotoxicity in clinical drug development was there
any concordance with animal toxicity studies.” These considerations as well as earlier studies
cited above suggest that the definition of concordance as in Eq. 1 is indeed robust. We are
currently investigating, using additional data and cheminformatics approaches, if there are
possible chemical determinants of concordance, i.e., if there are distinct classes of chemicals
for which animal data could be significantly more indicative of the expected effects in humans.
The results of these studies will be reported elsewhere.
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3.2. Clustering of compounds in chemistry space and gap-spotting in assertional meta-data
An initial quick examination of the 951 study compounds suggested a high level of dissimilarity
between their molecular structures. Nevertheless, we have applied clustering procedures to this
dataset to identify small groups of structurally similar compounds and assess whether they
possessed similar liver effect profiles. To this end, compounds were clustered using fragment
descriptors (see Figure 3) and the hierarchical algorithm of ISIDA/Cluster, as described in the
Methods section. The resulting dendrogram and the associated distance matrix represented by
the heat map are given in Figure 4. Analysis of this map revealed small clusters (located on
the diagonal of the map) with fairly high levels of chemical similarity between compounds.
We have focused on the assertional meta-data analysis of different clusters and asked the
following question: given that compounds within clusters have similar molecular structures,
how similar are they in terms of liver effect profiles across the three species? We should note
here that, as we began to review the similarity of liver effects, it became clear that a considerable
amount of non-rodent data was reporting 0 (i.e., according to our assumptions, the compounds
showed no liver effect in this species group). Given that the numbers of compounds reported
in the assertional meta-data for non-rodents was sparse, we felt that our initial assumption of
data completeness was perhaps weak in this case in terms of making any statistically significant
conclusions. For this reason, the non-rodent data were not considered for this analysis. The
following five case studies (CS) focus on liver effect profiles in humans and rodents; they are
also summarized in Table 2.
- CS 1: four compounds (barbital derivatives) make up this cluster. They have the same
chemical scaffold and are highly similar, and in fact, their liver effect profiles are exactly
the same: these compounds have been reported as producing liver effects in rodents only.
Follow-up assertion generation using MEDLINE did not identify any evidence for these
compounds having human liver effects. In addition, basic searches in Google (e.g. barbital,
human, hepatotoxicity) did not reveal evidence for these compounds having human liver
effects either. The apparent lack of human liver effects may be due to these compounds
being used for sedation/anaesthesia where lower doses and shorter exposures may be used
than in animal studies.
- CS 2: Both cladribine and clofarabine are anticancer drugs and have been identified as
producing liver effects in humans only. In contrast, cordycepin was found to report liver
effects in rodents only. Iterative assertion generation from MEDLINE failed to identify
any new evidence for cladribine and clofarabine having rodent liver effects. However, a
recent assertion in SIP, referenced by an EMEA EPAR did identify clofarabine as having
rodent liver effects (but still no rodent liver effects were identified for cladribine). It should
also be noted that follow-up assertion generation from MEDLINE did identify an effect
of cordycepin in a human hepatocellular cell line, as expected from our chemical similarity
analysis.
- CS 3: Four derivatives of 3-benzoyl-1-benzofuran are clustered together: amiodarone
(antiarrhythmic agent), benzarone (used for treatment of peripheral vascular disorders),
benzbromarone (uricosuric agent, used for gout), benziodarone (vasodilator). Three of
these compounds are reported to induce liver effects in humans and rodents. However,
benziodarone reported liver effects in rodents only, despite the high level of chemical
similarity between the four structures. As a result, one could suppose that this compound
should be tested (or re-tested) in human in vitro assays (e.g. hepatocytes) to confirm that
it does not produce liver effects. Follow-up assertion generation from MEDLINE did
not identify any new evidence for benziodarone having human liver effects. However, a
basic search in Google (e.g. benziodarone, human, hepatotoxicity) did reveal that the drug
was reported to cause hepatotoxicity in humans (Table 10 in
http://pubs.acs.org/doi/abs/10.1021/tx600260a). In fact, additional literature mining
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identified a report indicating that benziodarone was indeed withdrawn from the market in
the UK since 1964 for hepatotoxicity (29). This finding, prompted by our chemical
similarity analysis, illustrates the potential power of cheminformatics analysis to identify
possible gaps in the assertional meta-data derived from the literature.
- CS 4: This cluster is composed of five estrogen-like molecules. Once again, our analysis
allowed us to identify an interesting case: four among the five molecules were reported to
have liver effects in both humans and rodents: 2-methoxyestradiol, estradiol, estrone and
ethinyl estradiol. In contrast, estriol was not identified as producing liver effects in humans,
despite its high similarity to the other four molecules of this cluster. Follow–up assertion
generation from MEDLINE and a basic search in Google (e.g. estriol, human,
hepatotoxicity) did not identify any new evidence for estriol having human liver effects.
This observation of the apparent disparity between chemical similarity and liver effect
profiles remains puzzling.
- CS 5: The last example concerns six antibiotics with good structural similarity:
ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, norfloxacin and sparfloxacin. All
compounds report liver effects in humans. However, their liver effect profiles are different
for rodents. Follow-up assertion re-generation from MEDLINE did identify new evidence
for moxifloxacin having rodent liver effects. Basic searches in Google did not identify
evidence for gatifloxacin and levofloxacin to have rodent liver effects.
To briefly summarize these results, some clusters have been identified in which compounds
share similar molecular motifs, corresponding to similar liver effect profiles in humans and
rodents. However, in some clusters, one can observe that similar molecules possess different
liver effect profiles. These cases may correspond to missing or unreported data, and highlight
areas for gap-spotting or additional experimental investigation. Indeed, we have demonstrated
that additional, focused assertion re-generation using public sources led to modification of the
original profiles towards greater similarity, as expected for highly chemically similar
compounds. These results demonstrate the generally high accuracy of the assertional meta-
data retrieved by Sofia, while confirming the importance and validity of the cheminformatics
analysis of the links between chemical structure and assertions. Thus, our findings illustrate
the power of cheminformatics in spotting possible data gaps.
3.3. Analysis of chemical descriptor biases for species-specific assertions
Focussing on human and rodent data only, 248 molecules (236 + 12) – Class 1, have been
identified as reporting liver effects for humans only (see Figure 2). Yet, 283 different molecules
(257 + 26) – Class 2, showed liver effects for rodents only (i.e., these compounds have not
been reported as having liver effects in humans). In this section, we have examined if certain
chemical features are present in different proportions within these two datasets (classes 1 and
2), which could help identifying potential species-specific chemotypes. We used 2D fragment
descriptors of each compound and then, we determined important variations in the fragment
distributions within class 1 and class 2 separately.
The frequency distribution of the fragment descriptors is illustrated in Figure 5a. Results
indicate that two distinct categories of fragments can be identified based on their frequency
differences (ΔF) between the two classes of compounds (Figure 5b) (the analysis was also done
with frequency ratios leading to comparable conclusions):
(i) fragments with positive ΔF (found more frequently in class 1 than in class 2; see
Figure 5b): the highest ΔF values (more than 15%) are associated with amine-derived
fragments (C-N-C, C-C-C-N-C, C-C-C-N, C-C-N-C-C, C-C-N-C, C-N, C-C-C-N-C-
C, C-C-N) or aromatic rings including nitrogen atoms (C*N, C*C*N, * represent
aromatic bonds);
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(ii) fragments with negative ΔF (found more frequently in class 2 than in class 1) : for
example, O-C-C-C-O, C-C-C-C-C-O, C-O-C-C-C-O, C-C-C-C-O-C, O-C-C-C-C-O,
C-C-C-O-C (alcohol, ether and carboxylic acid substituted alkyl groups) have ΔF
smaller than – 5 %, as well as C*C*C-C-O (aromatic ring substituted by a methoxy
group or carboxyl group) or C-C-C=C-C=O (alkenes with a carbonyl group in α-
position).
This study is not exhaustive, and a more detailed list of chemotypes could be derived using
additional descriptors, such as the number of H-bond donors or acceptors, the number of rings,
etc. However, it follows from this analysis that some particular chemotypes influence certain
species-specific liver effects: for instance, in our dataset, 71 % (176 out of 248) of compounds
reporting liver effects in humans only (class 1) possess the fragment C-N-C (amine II), whereas
that fragment is present in only 48.8 % (138 out of 283) of compounds that report no liver
effects in humans (see Figure 5b) and in 53.7 % (216 out of 402) of compounds that report
liver effects in both humans and rodents. This information is not sufficient to conclude that the
presence of the amine group in a compound will result in a liver effect in humans. Moreover,
we stressed that such statistical analysis could be relatively biased by different issues: it is
obvious that certain classes of compounds known as being extremely toxic for human liver
would not be tested any longer; it is also clear that drug candidates being toxic for rodent liver
will be rejected early in the development process and thus will not be tested at all for humans.
It finally leads to important inaccuracies in the fragment statistics because of the weak
assumption of data completeness. However, we still believe that such frequency analysis is a
critical preliminary step in order to create a series of novel filters (or structural alerts) that can
be used to rapidly identify drug candidates likely to cause liver effects in humans.
3.4. QSAR modeling of drug-induced liver effects
Following the simple relative descriptor frequency analysis described above, we have
endeavoured to establish quantitative relationships between molecular structures and their
species-specific liver effects. We limited ourselves to the analysis of data reported for humans
and rodents because of scarcity of data reported for non-rodents (only 18 compounds reporting
liver effects in non-rodents only; see Figure 2). Indeed, from datasets A and B (see Table 1),
we could define two classes: 248 compounds inducing liver effects in humans only (class 1)
and 283 compounds inducing no liver effects in humans (class 2 – reported as causing liver
effects for rodents only). Based on this classification, we have derived QSAR classification
models with the SVM machine learning approach and two different types of molecular
descriptors: 2D fragments (described in section 3.3) and Dragon molecular descriptors (30).
Datasets A and B were merged (531 molecules) and randomly split into 5 modeling/external
sets (see Figure 6) to enable a 5-fold external Cross-Validation (CV; each compound is taken
one time only in an external test set). QSAR models were derived for the modeling set only
(i.e., internal 5-fold CV is done for each of the five modeling sets; models are selected if they
have reasonable statistical accuracy of both training and internal test set) and selected based
on prediction performances for the modelling set only. External test sets were never used to
derive or select the models. Our recently developed WinSVM program was used to generate,
select and apply models. The goal of our modelling studies was to obtain a series of predictive
classification QSAR models capable of separating compounds reporting liver effects in humans
from those that report no effects in humans, based on their chemical structure.
Prediction accuracies of the resulting models are given in Table 3. For each fold, the internal
5-fold CV performed on each modeling set led to SVM models with reasonable classification
accuracies ranging from 61.9 % to 67.5 %. When applied to the entire modeling set, SVM
models had high accuracies from 77.6 % to 99.3 %. Here, it should be pointed out that, in too
many published QSAR studies, only those latter results are reported to prove the high statistical
accuracy of the models. However, as we have pointed out in many publications (reviewed
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recently in (26)), rigorous external validation is a mandatory component of any QSAR study.
Thus, our internal 5-fold CV allowed an honest assessment of the model prediction abilities:
from the modeling set, we can realistically expect external predictions with an accuracy ranging
from 61.9 % to 67.5 %.
Concerning the `blind' prediction for the 5 external test sets, our models led (as expected) to
reasonable accuracies ranging from 55.7 % to 72.6 %, depending on the fold. Assessment of
these results shows a slightly better prediction accuracy reached by models built with fragment
descriptors (64.2 % to 72.6 %) compared to the models developed with Dragon descriptors
(55.7 % to 70.8 %). Y-randomization procedure applied to the modeling set, as a matter of
internal validation (discussed in (26)), was applied to the modeling set as a matter of an
additional internal validation. According to this popular statistical test, it is expected that
models built for the original datasets with shuffled target property (i.e., Y-randomized) should
have low accuracy of prediction for both training and test sets. Indeed, in our calculations,
models built with the Y-randomized target property (in our case, toxicity class assignment) led
to training set models with very low accuracies (40–50%) and very poor external prediction
performances. The failure of building QSAR models using this property randomization
procedure demonstrates the statistical significance and robustness of our validated DILI
prediction models. These `blind' predictions demonstrate the ability of our models to
successfully classify and thus segregate between compounds that affect human liver and those
that do not.
In order to test the prediction performance of our models, one may suggest applying them to
the set of 18 compounds reported as liver toxicants for non-rodents only (and thus, expected
to have no liver effects for humans according to our initial assumption). Indeed, we have found
that 14 among the 18 were correctly classified as non-toxicants for humans, leading to a fairly
good prediction accuracy of 77.8 % using SVM models built with fragment descriptors. To
further this analysis, we made use of our strategy for gap spotting in assertional data that was
discussed in section 3.2. To this end, we searched public data sources for additional information
concerning four apparently misclassified compounds. We noticed that one of these compounds,
i.e., sulfadoxine, is a very close chemical analog of sulfadimethoxine (see Figure 7), which
was, in fact, reported as a liver toxicant in humans (31). Indeed, the assertion re-generation
from MEDLINE did identify evidence for pyrimethamine/sulfadoxine (fansidar) causing
hepatitis in patients (NB: combinations of compounds were excluded from the original
analyses). This means that the prediction accuracy for the external set is likely to be 83% instead
of 78%.
4. Discussion
The main objective of our study was to explore the relationships between chemical structure
and species-specific liver effects using assertions derived by Sofia from published literature.
We have demonstrated that conventional cheminformatics approaches such as chemical
similarity analysis and QSAR modelling can be applied in a meaningful way to an observational
dataset that was generated by means of lexical, linguistic and ontological methods. In this
paper, we have addressed several important questions relevant to drug safety assessment.
First, we have explored the issue of concordance of liver effects across species. Since animal
testing is widely used both in environmental and drug discovery applications, as a substitute
of human studies, it is very important to understand in what cases the results of animal testing
are acceptable as accurate predictors of expected human effects. To this end, we have developed
a simple metric to calculate the pairwise concordance between species (Eq. 1) and found that
the concordance values between any two species from the three groups studied herein (humans,
rodents, non-rodent animals) were relatively low (40–45%). These results are in agreement
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with earlier studies reported in the literature (4;27;28). We should mention that, due to the
small amount of data for non-rodents, the conclusions for this species group may not be as
significant as those reached for human vs. rodent concordance analysis. We are currently
searching for additional species-specific DILI data and plan to revisit the issue of concordance
in future studies.
To enable the statistical analysis of species-specific drug-induced liver effects, we needed to
make an important (and perhaps somewhat speculative) assumption concerning the
completeness of the assertional meta-data. We have assumed that each compound was
effectively tested in all species and that the assertional meta-data represents a summary of all
known liver effects. Thus, if the assertional meta-data reported no liver effect for a particular
compound, we assumed that it has been tested and found not to produce a liver effect (see the
Methods section 2.2.2). There are two observations that may support this assumption. Firstly,
we only included compounds which are known active ingredients of therapeutic products that
either remain on the market or have been withdrawn. One would assume that any chemical
shown to be a toxicant in animal studies would be typically considered not suitable for human
use; however, a large number of compounds shown to produce liver effects in both humans
and rodents (as many as 292 in our studies according to the Venn diagram in Figure 2) implies
that the demonstration of these effects in rodents does not prevent compounds from human
exposure. It may follow then that there is a category of compounds that are toxic in rodents
but not toxic in humans. Furthermore, it is even more plausible that compounds only shown
to be toxic in humans were first tested in rodents and found to be safe. Thus, at least some of
our primary assumptions appear logical. But, most importantly, we believe that our ability to
achieve statistically significant and externally predictive QSAR models make it especially
plausible that our assumption about the completeness of the assertional meta-data has merits.
We did not, however, feel that we could make the same assumption for non-rodent data, given
that the number of compounds reporting liver effects in this group was much smaller than the
number of compounds reporting effects in humans and rodents. For this reason we decided to
exclude the non-rodent data from any QSAR modeling or fragment analysis exercise, because
the statistical rigor and the applicability domain of the resulting models would be very low.
The first part of our cheminformatics study identified series of molecular chemotypes
responsible for liver effects in a species-dependent manner. Such knowledge is key for
pharmaceutical companies to detect and eliminate potentially toxic drug candidates in early
stages of the drug development workflow. We have specifically verified the general principle
that highly chemically similar compounds have similar liver effect profiles across species.
Using clustering approaches frequently used in conventional cheminformatics research, we
have identified multiple small clusters of compounds with high structural similarity, and
confirmed that, for the most part, these compounds indeed had similar species-dependent liver
effect profiles. In several cases of discrepancy between chemical similarity and liver effect
similarity, we were able to revise the original assertions by additional focused re-mining of
public data. Furthermore, we have conducted a detailed analysis of 2D substructural molecular
fragments found both in compounds reporting liver effects in humans and those compounds
that do not, and isolated key chemical fragments that are statistically more frequently associated
with compounds inducing human liver effects. We are keenly interested in deepening the
understanding of structural determinants of liver effects, since these determinants translate into
structural alerts to filter out undesirable drug candidates in early stages of the drug discovery
process. A more detailed study on differential fragment frequency in compounds reporting
different liver pathologies is in progress.
The second cheminformatics part of this study was dedicated to QSAR modeling, with the goal
of establishing quantitative models of chemically-induced liver effects in humans. Using a
reduced and curated dataset, we have built classification models that could predict, with high
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accuracy, if a compound is likely to produce liver effects in rodents-only (which we interpreted
as NOT producing liver effects in humans) or in humans-only. The best models were selected
following an external 5-fold CV procedure. Two types of descriptors have been employed:
Dragon and 2D fragment descriptors. From our internal 5-fold CV performed on the modeling
set for each of the five splits, we found that our computational models can realistically reach
external predictions with an accuracy ranging from 61.9 % to 67.5 %, pretty much in line with
experimental in vitro data (10). Perhaps surprisingly, given the extreme diversity of chemical
structures and the unconventional source of the liver data (i.e., assertions generated from the
literature using automated extraction procedures), SVM QSAR models showed high external
prediction accuracies ranging from 55.7% to 72.6%.
It should be pointed out that the splits in the external 5 fold cross-validation have been done
randomly without any study of the distribution of chemicals into the splits (except that each
compound is present in the external test set only once). So the potential overlap between
modeling and external test sets in terms of chemical space is excluded by the virtue of the
method used to build and validate models. Y-randomizations of the modeling set led to poor
models with low accuracies (40–50%) and constant outputs whatever the compounds,
demonstrating the robustness of our models. The results of these modeling studies serve to
validate the consistency of the data and reassure the rigor of the data collection and curation
procedures, in a sense, lending some statistical support to our main assumption about the
`completeness' of the dataset (except for non-rodents). In this study, regarding the raw nature
of the data provided by a literature-mining platform, it seemed to us that the application of a
massive QSAR strategy involving many machine learning approaches (such as multi-linear
regressions, artificial neural networks, random forest etc.) was not appropriate since our first
goal was simply to demonstrate the feasibility of using cheminformatics approaches for the
analysis and refinement of data generated from mining literature sources. Therefore only SVM
models with two different types of chemical descriptors have been built.
Finally, we made every attempt to prove the accuracy of our models using external datasets.
As a corollary to the analysis described in this paper, we have mined the EMEA EPARs
database for compounds having liver effects. This resulted in a set of 44 compounds reported
to induce liver effects in humans only. After removing compounds already present in our
modeling set, 34 molecules remained. The consensus SVM model employing individual
validated SVM models built with both fragment and Dragon descriptors afforded a good
prediction accuracy (67.6%) for this additional external validation set. Specifically, 23 out of
34 compounds were indeed predicted to produce liver effects in humans, whereas 11
compounds were classified as non-toxic. 2 out of these 11 compounds were found to fall outside
of the models' domain of applicability (defined based on chemical similarity threshold in the
descriptor space as described in (32;33). Moreover, as illustrated in Figure 8, analysis of
apparently misclassified compounds revealed the importance in the choice of the modeling set:
for instance, bimatoprost was reported to produce human liver effects in the EMEA dataset of
34 molecules, but was misclassified by our QSAR models as non-toxic. The nearest neighbor
of bimatoprost (based on structural similarity in the descriptor space) in the modeling set of
531 compounds is iloprost which has not been reported to produce liver effects in humans.
Considering the entire human set of 650 compounds as a potential modeling set, the nearest
neighbor of bimatoprost is now prostaglandin F2a, annotated as producing liver effects in
humans. Thus, beyond the modeling exercise reported in this study, and following the objective
of building an efficient predictor of DILI in humans, we will have to build additional models
trained on an enlarged set, including all compounds reporting human liver effects in our dataset,
to avoid basic misclassification, as in the case of bimatoprost.
Additional mining of MEDLINE, conducted after this study was completed, afforded an
additional external dataset of 246 compounds; 92 annotated as “causing effects in humans
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only” and 154 as “causing effects in rodents only”. External prediction accuracies varied from
65.4% to 67.5% using our WinSVM models and Dragon descriptors. The removal of structural
outliers, using the applicability domain implementation, led to a reduced set of 222 compounds
(90.2% coverage of the dataset) with a prediction accuracy of 67.6%. These results agree
quantitatively with external prediction accuracies generated with the original dataset using 5-
fold external CV and other external sets. This additional analysis adds weight to the robustness
of the overall approach and to the power of combining the expertise in comprehensive assertion
generation and cheminformatics in the analysis of chemically-induced liver effects (see Figure
1).
5. Conclusions
We have employed conventional cheminformatics approaches to analyze assertions of drug-
induced liver effects in different species, retrieved by a novel approach comprising lexical and
linguistic extraction and ontology-based methods. After a critical step of chemical data
curation, cluster analysis of the remaining 951 compounds allowed us to identify multiple
clusters in which compounds belong to structurally congeneric series. Similar liver effect
profiles have been observed for most clusters although some compounds appeared as outliers.
In several cases of such outliers, additional focused mining of public data sources led to revised
assertions that were more in tune with liver effect profiles expected on the basis of chemical
similarity. QSAR models were generated to predict liver effects of compounds in humans from
chemical structure. Despite the apparent chemical diversity of the modeling set, an uncommon
source of biological data, and the apparent complexity of underlying biological mechanisms
the models showed good prediction power as assessed by five-fold external CV procedures.
The external predictivity of models was further confirmed by applying them to different
external sets of compounds.
We believe that the studies reported in this paper present the first example of combining
rigorous text mining and cheminformatics data analysis towards establishing predictive models
of chemical toxicity. This work suggests that cheminformatics approaches could find a
prominent place in refining the compound annotations resulting from biomedical text mining.
The approach could be described in two steps: (1) launch a deeper literature- and internet-
mining to search for evidences concerning the compound in question; (2) if nothing is retrieved
from (1), we could at least add a warning sign for this compound as a potential safety alert on
a dedicated website and suggest that supplementary experimental assessments are needed.
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The general study design workflow.
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Venn diagram representing 951 compounds classified according to their liver effects for
humans (650 compounds), rodents (685) and non-rodents (166).
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Examples of substructural fragment descriptors, and the corresponding pattern matrix for the
clustering of compounds in chemistry space.
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Heat map representing the distance matrix (left) between compounds and the corresponding
dendrogram (right): the map is colored according to the chemical similarity between
compounds (blue-violet: high similarity; yellow-red: low similarity); small clusters with high
levels of chemical similarity can be identified on the diagonal of the matrix.
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(a) Frequency analysis of fragment descriptors (X axis) in class 1 (compounds inducing liver
injuries for humans) and class 2 (compounds inducing no liver injuries for humans). (b) List
of fragment descriptors that are more frequent in class 1 than in class 2.
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QSAR modeling workflow for drug-induced liver effects in humans.
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The chemical structure of sulfadoxine (a), which was misclassified by our QSAR models (i.e.,
predicted to produce liver effect in humans), compared to the structure of sulfadimethoxine
(b) included in the modeling set and reported later to have liver effects in humans.
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Nearest neighbors of bimatoprost in the modeling set of 531 compounds and the entire human
dataset of 650 compounds.
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Table 2
Examples of five clusters identified within the entire library of 951 compounds. For each compound, its
assertional meta-data profile is also shown (“1” = liver effect; “0” = no liver effect).
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Table 3
Prediction accuracies obtained by the selected classification QSAR models for the 5-folds, using the SVM
machine learning approach and two types of descriptors.
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